A review of pediatric obesity treatments compared medications, lifestyle programs and combinations through a network of 42 trials [1]. Research on how long teens stay on GLP-1 drugs addresses a separate question about continuation in routine care. This review focused on outcomes over roughly six to twelve months.
What the review found
Structured lifestyle treatment alone was associated with a BMI reduction of 3.85 points versus control [1]. The 95% confidence interval was 2.80 to 4.91 points. The estimate for semaglutide plus counseling was 8.31 points, with a 95% confidence interval of 4.28 to 12.33. The authors traced the semaglutide estimate to one relatively small trial.
The review reported larger BMI reductions with medication plus lifestyle support than with medication alone in its network. The Taiwan study of liraglutide in adolescents shows the different questions that can be answered by following one group in routine care. The network combined direct comparisons and statistical estimates across trials, so these numbers cannot rank every option for an individual.
What the review did not measure well
The programs varied in their intensity and included different types of support. The review could not establish which counseling format works best with a given medication. It also had limited evidence on long-term outcomes and on how body composition changed with newer drugs.